Dual-targeting BCMA/CD19 CAR-T(Ucello Therapeutics) in Systemic Lupus Erythematosus: NCT07274059 Clinical Landscape Report 2026
Explore the PatSnap Life Sciences MCP marketplace
This Clinical Landscape Report was built with PatSnap Life Sciences MCP workflows. Clinical Trials MCP supplies protocol and result records, Drug & Asset MCP adds asset context, and Company & Deal Intelligence MCP resolves sponsor background. Use the same structured MCP building blocks in your research workflow.
Data snapshot: 28 September 2026. This strategic research report is not medical, regulatory or investment advice. Trial status and dates can change.
Early Phase 1
Clinical phase
Recruiting
Recruitment status
48
Planned enrollment
2035-12-31
Primary-completion proxy
Executive view
NCT07274059 evaluates Dual-targeting BCMA/CD19 CAR-T(Ucello Therapeutics) in Systemic Lupus Erythematosus. The disclosed sponsor is Chengdu Ucello Biotechnology Co., Ltd., the design is Interventional, and the geographic footprint is China. The first listed primary endpoint is the incidence rate of Dose limited toxicity (DLTs), assessed over Up to 28 days after infusion.
The key landscape question is whether this protocol can generate a clinically interpretable signal relative to nearby programs. Phase alone is not a measure of evidence quality. Endpoint relevance, comparator choice, masking, enrollment feasibility, patient selection, country coverage and follow-up must be considered together.
PatSnap MCP Servers make this assessment reproducible by keeping protocol facts, result evidence, asset attributes and sponsor identity in separate structured calls.
How the MCP evidence stack was assembled
Clinical Trials MCP clinical_trial_fetch retrieved the design, outcomes, phase, status, enrollment, sponsor, countries and timing for NCT07274059 and selected peers. clinical_trial_result_fetch supplied detailed result records from the wider Systemic Lupus Erythematosus landscape. Drug & Asset MCP drug_fetch was queried for Dual-targeting BCMA/CD19 CAR-T(Ucello Therapeutics), while Company & Deal Intelligence MCP organization_fetch was queried for Chengdu Ucello Biotechnology Co., Ltd..
This separation reduces a common diligence error: treating a registry label, a company description or a result excerpt as if each represented the complete evidence package. Explore the source workflow at the PatSnap MCP marketplace.
Trial landscape table
| Trial | Asset / intervention | Phase / status | Sponsor | Geography | Primary endpoint | Readout proxy |
|---|---|---|---|---|---|---|
| NCT07274059 | Dual-targeting BCMA/CD19 CAR-T(Ucello Therapeutics) | Early Phase 1 / Recruiting | Chengdu Ucello Biotechnology Co., Ltd. | China | the incidence rate of Dose limited toxicity (DLTs) Up to 28 days after infusion | 2035-12-31 |
| NCT07331467 | MC150 | Phase 1 / Recruiting | Chongqing Precision Biotechnology Co., Ltd. | China | The safety of CAR-T cell therapy in patients with refractory SLE [Safety] 3 months | 2026-07-01 |
| NCT07332481 | Enpatoran | Phase 3 / Recruiting | EMD Serono Research & Development Institute, Inc. | Romania, United States, Japan, Switzerland, Spain, South Korea, Taiwan Province, Poland, Italy, Slovakia, Israel, France, Bulgaria, Germany | Percentage of Participants With Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) 70 Response, Defi… At Week 24 | 2029-05-24 |
| NCT07333118 | GT801 | Early Phase 1 / Recruiting | Zhuhai Grit Biotechnology Co., Ltd. | China | Proportion of participants experiencing dose limiting toxicity 28 days post GT801 infusion | 2028-03-31 |
| NCT07328581 | BCMA-CD19 cCAR-T cell therapy (iCell Gene Therapeutics) | Phase 2 / Recruiting | iCell Gene Therapeutics, Inc. | United States | Number of Adverse Events after ICG318 infusion Starting day 0 and up to 1 year after ICG318 infusion. | 2028-12-01 |
The table aligns endpoints, sponsors, phases, geographies and readout proxies. It is descriptive, not a head-to-head efficacy comparison. Differences in population, baseline risk, intervention schedule and follow-up can dominate apparent cross-trial differences.
Reproduce the trial-to-asset workflow with PatSnap MCP
Protocol design and endpoint interpretation
NCT07274059 is a Early Phase 1, recruiting study with 48 planned participants. Allocation is N/A, masking is None (Open Label), and the intervention model is Single Group Assignment.
The primary endpoint is “the incidence rate of Dose limited toxicity (DLTs)” over “Up to 28 days after infusion.” The retrieved endpoint description is: Dose limited toxicity(DLT) was defined as the occurrence of any of the following adverse events within 28 days of the infusion of UCAR-T cells..
Interpretation should test whether the endpoint captures a clinically meaningful change, whether its time horizon matches the proposed biology, and whether treatment discontinuation or missing data can bias the estimate. The planned enrollment of 48 should be assessed against expected effect size, event frequency, multiplicity, subgroup plans and attrition.
No named control drug was returned in the protocol field set. A placebo comparator can strengthen internal efficacy assessment, while an active comparator may better test clinical differentiation. Single-arm and open-label programs require greater weight on objective outcomes, independent assessment and external benchmarks.
Indexed readouts in the surrounding landscape
5 recent result records were selected as contextual evidence for Systemic Lupus Erythematosus. These records do not establish direct evidence for NCT07274059 unless the registration number matches.
A PHASE 2, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE CLINICAL EFFECT, PHARMACODYNAMIC, PHARMACOKINETIC AND SAFETY PROFILE OF PF 06823859 IN A…
Phase 2; n=8; Change From Baseline in Type 1 Interferon (IFN) Gene Signature (GS) Score in Lesional Skin at Week 12(Least Squares Mean): Least Square Mean Difference = 0.5(90% CI, -3.7 to 4.6), P-Value = 0.8243; Change From Baseline in Type 1 Interferon (IFN) Gene Signature (GS) Score in Lesional Skin at Week 12(Least Squares Mean): Least Square Mean Difference = 0.5(90% CI, -3.7 to 4.6), P-Value = 0.8243 Source: https://clinicaltrials.gov/ct2/show/results/NCT05879718
A Phase 2a, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of MK-6194 in Adult Participants With Systemic Lupus Erythematosus
Phase 2; n=149; Number of Participants Achieving Systemic Lupus Erythematosus Responder Index (SRI-4) Response at Week 28 = 10 Participants ; Number of Participants Achieving Systemic Lupus Erythematosus Responder Index (SRI-4) Response at Week 28 = 15 Participants Source: https://clinicaltrials.gov/ct2/show/results/NCT06161116
Dapagliflozin in lupus nephritis: renal and hematologic outcomes from a randomized controlled trial
Phase 2; n=79; eGFR = -2.0 ml/min/1.73 m2 Source: https://pubmed.ncbi.nlm.nih.gov/42549085/
Result fields should be reconciled with the source record before quantitative comparison. Population definitions, analysis sets, dose cohorts, estimands, confidence intervals, rescue therapy and follow-up can materially change the meaning of a numerical endpoint. Clinical Trials MCP supports repeatable refreshes as result records change.
Asset and sponsor context
Dual-targeting BCMA/CD19 CAR-T(Ucello Therapeutics) is indexed as CAR-T with target not reported biology and a global stage of Phase 1. The asset profile lists Chengdu Ucello Biotechnology Co., Ltd. as an originator or developer.
Chengdu Ucello Biotechnology Co., Ltd. is indexed in China. The organization record is used to resolve sponsor identity. The record lists 7 development-stage drug assets.
For execution diligence, monitor sponsor ownership, collaborator additions, site expansion, protocol amendments and enrollment revisions. A change in ownership or geography can alter operational confidence as well as the commercial meaning of a future readout.
Development white space
- Endpoint white space. Determine whether a more patient-relevant outcome, longer durability window or blinded central assessment would resolve uncertainty left by the current endpoint.
- Population white space. Test biomarker-defined, treatment-line or risk-stratified subgroups where effect size and unmet need could be clearer.
- Comparator white space. Identify whether the study can support differentiation against the current standard of care rather than only activity against baseline or placebo.
- Geographic white space. Assess whether the disclosed footprint supports recruitment, regulatory transferability and commercial generalizability.
- Sequencing white space. Clarify whether Dual-targeting BCMA/CD19 CAR-T(Ucello Therapeutics) is intended for monotherapy, combination, maintenance, rescue or an earlier treatment line.
White space should be framed as an unanswered development question, not merely an unoccupied mechanism label. A credible program closes a measurable clinical uncertainty with a design that can be executed and interpreted.
Strategic implications and next readouts
For sponsors, the endpoint hierarchy, safety window, enrollment pace and protocol amendment history should all support the same target product profile. Advancement criteria should be set before the readout and tied to clinical effect, uncertainty, tolerability and operational feasibility.
For business-development teams, differentiation may come from a sharper population, stronger comparator, more durable benefit, simpler delivery or clearer sequencing role. For investors, the central risk is evidence quality relative to time and capital, not the phase label in isolation.
Track recruitment status, enrollment changes, primary-completion timing, endpoint revisions, new result records, sponsor ownership and collaborator changes. Re-run the PatSnap MCP workflow when a surrogate becomes a clinical outcome, a single-country study expands, the comparator changes or a new result materially shifts the competitive benchmark.
Source trail and bottom line
Anchor trial: NCT07274059
Protocol source: https://clinicaltrials.gov/study/NCT07274059
MCP sources: Clinical Trials MCP (clinical_trial_fetch and clinical_trial_result_fetch); Drug & Asset MCP (drug_fetch); Company & Deal Intelligence MCP (organization_fetch).
Data snapshot: 28 September 2026.
Dual-targeting BCMA/CD19 CAR-T(Ucello Therapeutics) in Systemic Lupus Erythematosus is best understood through the interaction of protocol design, surrounding readouts, asset context and sponsor execution. The current record makes the incidence rate of Dose limited toxicity (DLTs) and 2035-12-31 the leading decision points.
Build and refresh clinical landscape reports with PatSnap MCP
